Evaluating only Clovis Oncology’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Clovis Oncology founded
REGULATORY ACTION
Regulatory pressure escalates
SHUTDOWN
Bankruptcy: Clovis Oncology ceases operations
Full Analysis
Free · no account needed
Documented cause
Clovis Oncology built its business around rucaparib (Rubraca), a PARP inhibitor for ovarian and prostate cancer. It raised $700M and went public in 2014. Rubraca was approved but in an increasingly competitive PARP inhibitor class where AstraZeneca Lynparza and GlaxoSmithKline Zejula had superior clinical data and deeper commercial infrastructure. The FDA progressively restricted Rubraca indications based on survival data. In January 2023, Clovis filed for Chapter 11 with $2B+ in accumulated losses, unable to generate sufficient commercial revenue to service debt.
Lesson
“One-drug oncology companies face existential risk when the therapeutic class has multiple well-funded competitors. The PARP inhibitor class effectively required Clovis to have superiority data versus Lynparza and Zejula simultaneously — a clinical bar that required being first in all indications, which Clovis was not.”